Pan-RAF Inhibitors for Paediatric Low-grade Gliomas Offer New Opportunities in Targeted Therapy

Abstract

Low-grade gliomas are the most common brain tumour to occur in childhood. The identification of the mitogen-activated protein kinase pathway as the near-uniform driver of these tumours has led to the testing of therapies targeted at this pathway, with promising early results. The pan-RAF inhibitor tovorafenib is one of the most recent targeted agents to be tested for paediatric low-grade gliomas, with early data raising the prospect that we may be at the dawn of a new era in the management of this childhood brain tumour.